查找临床试验
已按「胃肠间质瘤」检索，对应国际通用词 gastrointestinal stromal tumor
共找到 38 项正在招募的试验（在欧美日韩等发达国家设有中心）
数据更新于 00:25，每 5 分钟自动同步A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
United States、Australia、Canada、France、Germany 等 12 国
年龄 8 Years – 不限
Fore Biotherapeutics
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)
United States
年龄 18 Years – 不限
Kumquat Biosciences Inc.
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
United States、Argentina、Australia、Brazil、Canada 等 12 国
年龄 18 Years – 不限
GlaxoSmithKline
The Efficacy and Safety of Temozolomide in SDH-deficient GIST
South Korea
年龄 20 Years – 不限
Asan Medical Center
Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients
United Kingdom
年龄 18 Years – 不限
Royal Marsden NHS Foundation Trust
LRG GIST Patient Registry
United States
年龄 不限 – 不限
The Life Raft Group
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
United States
年龄 18 Years – 不限
Deciphera Pharmaceuticals, LLC
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
United States
年龄 18 Years – 不限
University of Miami
Long-term Survivorship Challenges of Advanced/Metastatic GIST Patients Responding to Tyrosine Kinase Inhibitor Treatment: an Observational Study
Netherlands
年龄 18 Years – 不限
The Netherlands Cancer Institute
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
South Korea
年龄 20 Years – 不限
Asan Medical Center
Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients
South Korea
年龄 20 Years – 不限
Asan Medical Center
RCT of EFTR Versus STER for GIST Treatment
China、Hong Kong、India、Japan
年龄 18 Years – 75 Years
Chinese University of Hong Kong